QAX576

( DrugBank: - / KEGG DRUG: - )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
85	特発性間質性肺炎	3

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	3
98	好酸球性消化管疾患	1

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00581997 (ClinicalTrials.gov)	December 2007	21/12/2007	QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis	A Randomized, Double-blinded, Placebo Controlled, Multiple-dose, Multi-center Pilot Study, to Assess ...	Pulmonary Fibrosis Secondary to Systemic Sclerosis	Drug: QAX576;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	Both	8	Phase 2	United States

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020688-18-GB (EUCTR)	29/06/2011	28/01/2011	Safety and Efficacy of QAX576 in Patients With Progressive Idiopathic Pulmonary Fibrosis (IPF)	A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to ...	Patients with rapidly progressive idiopathic pulmonary fibrosis MedDRA version: 14.1;Level: PT;Class ...	Product Code: QAX576	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	40		United Kingdom
2	NCT01266135 (ClinicalTrials.gov)	December 2010	17/12/2010	Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to A ...	Idiopathic Pulmonary Fibrosis	Drug: QAX576;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	80 Years	All	40	Phase 2	United States;United Kingdom
3	NCT00532233 (ClinicalTrials.gov)	September 2007	19/9/2007	SD, IL-13 Production Rate in IPF	A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576to Determine IL-13 Producti ...	Idiopathic Pulmonary Fibrosis	Drug: QAX576	Novartis Pharmaceuticals	NULL	Completed	40 Years	80 Years	All	52	Phase 2	United States

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01355614 (ClinicalTrials.gov)	June 2011	16/5/2011	A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients	A Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tol ...	Crohn's Disease	Drug: QAX576;Drug: Infliximab	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	10	Phase 2	Germany;Switzerland
2	EUCTR2010-019973-13-DE (EUCTR)	14/01/2011	30/09/2010	A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients	A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tol ...	Treatment of perianal fistulas in patients suffering from Crohn's Disease. MedDRA version: 14.0;Leve ...	Product Code: QAX576 Trade Name: Remicade INN or Proposed INN: INFLIXIMAB	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	23	Phase 2	Germany;Switzerland
3	NCT01316601 (ClinicalTrials.gov)	January 2011	14/3/2011	A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576in t ...		Crohn's Disease	Drug: QAX567	Gerhard Rogler	Novartis Pharmaceuticals	Completed	18 Years	N/A	Both	3	Phase 2	Switzerland

臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01022970 (ClinicalTrials.gov)	November 2009	25/11/2009	Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis	A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576in the Treatment of Eosino ...	Eosinophilic Esophagitis	Drug: QAX576 placebo;Drug: QAX576	Novartis Pharmaceuticals	NULL	Completed	18 Years	50 Years	All	25	Phase 2	United States